- Conditions
- Congenital Heart Disease
- Interventions
- Blood Sample Collection
- Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2030
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 574
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Cancer
- Interventions
- Surveys
- Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Vomiting, Migraines
- Interventions
- Not listed
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pain
- Interventions
- Pain Medication DNA Insight (TM) test
- Genetic
- Lead sponsor
- Defense and Veterans Center for Integrative Pain Management
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Fort Bragg, North Carolina
- Conditions
- Hypogonadism, Hypogonadotropic, Kallmann Syndrome
- Interventions
- Not listed
- Lead sponsor
- Boston College
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 227 participants
- Timeline
- 2018 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Chestnut Hill, Massachusetts
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
- Interventions
- Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1405
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
- Conditions
- Pheochromocytoma, Paraganglioma, Inherited Cancer Syndrome, Associated Conditions, Kidney Neoplasms, Bone Cancer, Thyroid Neoplasms, Other Cancer
- Interventions
- Genetic screening
- Genetic
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- Not listed
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2030
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Trisomy 13, Trisomy 18, Trisomy 21, Aneuploidy
- Interventions
- Blood Draw
- Procedure
- Lead sponsor
- Natera, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 937 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2023
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Malignant Hyperthermia
- Interventions
- Whole exome sequencing
- Genetic
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2037
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Macular Degeneration, Geographic Atrophy, Stargardt Disease
- Interventions
- Observational
- Other
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Down Syndrome, Fetal Aneuploidy
- Interventions
- Not listed
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 6 more
- Conditions
- Lung Neoplasms, Carcinoma Non-small-cell Lung
- Interventions
- Multifocal Tissue Banking
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Phenylketonurias
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- Not listed
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Decatur, Georgia
- Conditions
- Breast Cancer, Ovarian Cancer, Uterine Cancer
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lung Cancer
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
- Interventions
- Gene Therapy product-MCO-010
- Biological
- Lead sponsor
- Nanoscope Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
- Conditions
- Intracranial Aneurysm
- Interventions
- Not listed
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Arthritis
- Interventions
- Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
- Other
- Lead sponsor
- Proove Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 31
- States / cities
- Beverly Hills, California • Fresno, California • La Jolla, California + 23 more
- Conditions
- Metastatic Prostate Carcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
- Interventions
- Training and Education, Educational Intervention, Discussion
- Behavioral · Other · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Eleclazine, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
- Conditions
- Cystic Fibrosis, Chronic Bronchitis
- Interventions
- IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin
- Drug
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 8
- States / cities
- Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more
- Conditions
- Cancer
- Interventions
- Not listed
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Infertility, Female
- Interventions
- Preimplantation genetic testing for aneuploidy (PGT-A)
- Procedure
- Lead sponsor
- Genomic Prediction Inc.
- Industry
- Eligibility
- 35 Years to 40 Years · Female only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Margate, Florida